Who founded Antios Therapeutics?

Antios Therapeutics was founded by Gregory Mayes in 2018.

Who are Antios Therapeutics's investors?

Antios Therapeutics's investors include Aisling Capital, Altium Capital, Avego BioScience Capital, Pontifax Venture Capital.

How much funding has Antios Therapeutics raised?

Antios Therapeutics has disclosed $126.4M raised across 4 rounds.

Where is Antios Therapeutics headquartered?

Antios Therapeutics is headquartered in Mendham, US.

Antios Therapeutics

Mendham, US · Founded 2018 · Delaware corporation · 4 known investors

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program. Its treatments aim to suppress HBV replication and work toward a functional cure for HBV-infected patients.

Biotech Healthtech

Founders & leadership

Antios Therapeutics was founded in 2018 by Gregory Mayes.

Gregory MayesFounder

Douglas MayersExecutive

Tamra AdamsExecutive

Abel De La RosaNamed on SEC filing

Board

Iyona Rajkomar inBoard directorPartner at Pontifax Venture Capital

Benjamin RovinskiBoard director

Patrick HigginsBoard director

Scott MorensteinBoard director

David CannerBoard director

Investors · 4

Aisling CapitalNew York

Altium CapitalNew York

Avego BioScience CapitalAlpharetta

Pontifax Venture CapitalHerzeliya · $6.3M – $128M

Reported raises · per SEC filings

Form D private placements

$126.4M disclosed across 4 rounds · 2018–2021

▶$75MraisedNov 2021 · 35 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Benjamin RovinskiDirector
Scott MorensteinDirector
Tamra AdamsExecutive Officer
Craig GordonDirector
Gregory MayesExecutive Officer, Director
Abel De La RosaDirector
Douglas MayersExecutive Officer
Patrick HigginsDirector
Iyona RajkomarDirector

Offering amount: $86M
Amount sold: $75M
First sale: Nov 2021
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$32MraisedApr 2021 · 29 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Abel De La RosaDirector
Iyona RajkomarDirector
Douglas MayersExecutive Officer
Benjamin RovinskiDirector
Patrick HigginsDirector
Tamra AdamsExecutive Officer
Scott MorensteinDirector
David CannerDirector
Gregory MayesExecutive Officer, Director

Offering amount: $100M
Amount sold: $32M
First sale: Apr 2021
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$4.4MraisedAug 2020 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Idean MarvastyExecutive Officer
Douglas MayersExecutive Officer
Abel De La RosaExecutive Officer, Director
Nicole VitulloDirector
Henry Lin ChenDirector
Benjamin RovinskiDirector
Scott MorensteinDirector

Offering amount: $5M
Amount sold: $4.4M
First sale: Jul 2020
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$15MraisedDec 2018 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Benjamin RovinskiDirector
Abel De La RosaExecutive Officer, Director
Nicole VitulioDirector
Henry Lin ChenDirector
Douglas MayersExecutive Officer
Scott MorensteinDirector
Idean MarvastyExecutive Officer

Offering amount: $25M
Amount sold: $15M
First sale: Nov 2018
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Artios Pharma3 shared keywordsArtios develops DNA Damage Response (DDR)-based therapeutics for hard-to-treat solid tumors, including small-molecule inhibitors targeting ATR (alnodesertib) and DNA polymerase theta (ART6043). The company operates a proprietary DDR drug-development platform called DcoDeR and advances a pipeline of oncology product candidates through clinical trials.

Companies competing with Antios Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Antios Therapeutics do?: Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program. Its treatments aim to suppress HBV replication and work toward a functional cure for HBV-infected patients.
Who founded Antios Therapeutics?: Antios Therapeutics was founded by Gregory Mayes in 2018.
Who are Antios Therapeutics's investors?: Antios Therapeutics's investors include Aisling Capital, Altium Capital, Avego BioScience Capital, Pontifax Venture Capital.
How much funding has Antios Therapeutics raised?: Antios Therapeutics has disclosed $126.4M raised across 4 rounds.
Where is Antios Therapeutics headquartered?: Antios Therapeutics is headquartered in Mendham, US.